BioSpace News Archive

Invitae (NYSE: NVTA), a leading medical genetics company, today announced preliminary unaudited fourth quarter and full-year 2022 revenue, cash burn and commercial metrics.

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022, making it the most successful product announcement in PacBio’s history.

TRex Bio, Inc., (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to develop novel therapies for the treatment of immune-mediated diseases.

bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference.

Neuralace Medical, Inc., a commercial-stage medical technology company providing innovative, non-invasive solutions for the treatment of chronic neuropathic pain, is announcing the signing of a $1.4M, five year contract with the Department of Veterans Affairs, Augusta, GA VA.

Nicox SA announced its intention to move its listing from the Euronext Paris regulated market to Euronext Growth Paris and convened for this purpose an ordinary shareholder meeting on Tuesday February 14, 2023 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne - France.

CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.

Masimo announced the results of a prospective study published in the American Journal of Emergency Medicine in which Dr. Zohair Ahmed Ali Al Aseri and colleagues at King Saud University Medical City and Dar Al Uloom University evaluated the performance of noninvasive spot-check hemoglobin measurement with Masimo SpHb® on emergency department patients.

Hemogenyx Pharmaceuticals plc announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor platform technology, designed to program immune cells to eliminate viral infections by destroying the viruses that cause them.

Orexo AB, announces the company has initiated two exploratory feasibility studies, applying the proprietary drug delivery platform amorphOX® to protein based pharmaceuticals and vaccines in collaboration with leading international biopharmaceutical and vaccine companies.